magnify
Home Wetenschappelijke artikelen

Wetenschappelijke artikelen

Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with restless legs syndrome 2016


Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with restless legs syndrome.
Halac G, Kilic E, Cikrikcioglu MA, Celik K, Toprak-Erek A, Keskin S, Gultepe I, Celik RS, Ozaras N, Yildiz A, Aydin S, Akan O, Karatoprak C, Sekin Y, Asil T.

A TRAPPC6B splicing variant associates to restless legs syndrome. Parkinsonism Relat Disord 2016


Aridon P1, De Fusco M2, Winkelmann JW3, Zucconi M4, Arnao V5, Ferini-Strambi L4, Casari G6. A TRAPPC6B splicing variant associates to restless legs syndrome. Parkinsonism Relat Disord. 2016 Oct;31:135-138. doi: 10.1016/j.parkreldis.2016.08.016. Epub 2016 Aug 18

Sleep Med. Default mode network disturbances in restless legs syndrome/Willis-Ekbom disease 2016


Ku J1, Lee YS2, Chang H3, Earley CJ4, Allen RP4, Cho YW5.
Sleep Med. Default mode network disturbances in restless legs syndrome/Willis-Ekbom disease 2016 Jul;23:6-11. doi: 10.1016/j.sleep.2016.05.007. Epub 2016 Jul 6.
[5] Aridon P1, De Fusco M2, Winkelmann JW3, Zucconi M4, Arnao V5, Ferini-Strambi L4, Casari G6. A TRAPPC6B splicing variant associates to restless legs syndrome. Parkinsonism Relat Disord. 2016 Oct;31:135-138. doi: 10.1016/j.parkreldis.2016.08.016. Epub 2016 Aug 18.

Central and peripheral nervous system excitability in restless legs syndrome. 2016


Central and peripheral nervous system excitability in restless legs syndrome.
Lanza G1, Bachmann CG2, Ghorayeb I3, Wang Y4, Ferri R5, Paulus W6

Whole body and local cryotherapy in restless legs syndrome: A randomized, single-blind, controlled parallel group pilot study. 2016


[2] Happe S1, Evers S2, Thiedemann C1, Bunten S3, Siegert R4. J Neurol Sci. Whole body and local cryotherapy in restless legs syndrome: A randomized, single-blind, controlled parallel group pilot study.
2016 Nov 15;370:7-12. doi: 10.1016/j.jns.2016.09.006. Epub 2016 Sep 9.

A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation. 2016


[1] A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
Winkelman JW1, Mackie SE2, Mei LA3, Platt S3, Schoerning L4. Kurt O Yazici CM et al. Scand J Urol. 2016 Jun 22:14.

____________________________________________________________________________________________________________

Is it only a sleeping disorder or more? Restless legs syndrome and erectile function. 2016


[1] Is it only a sleeping disorder or more? Restless legs syndrome and erectile function. Kurt O Yazici CM et al. Scand J Urol. 2016 Jun 22:14.

Evaluation of neurodegeneration through visual evoked potentials in restless legs syndrome. 2016


[2] Evaluation of neurodegeneration through visual evoked potentials in restless legs syndrome. Kısabay A1, Sarı US2, et al, Acta Neurol Belg. 2016 Apr 6. [Epub ahead of print].

Augmentation and impulsivity in restless legs syndrome patients: A complex interaction. 2016


[3] Augmentation and impulsivity in restless legs syndrome patients: A complex interaction. O’Sullivan SS1, Poyares D2. Neurology. 2016 Jun 3. pii: 10.1212/WNL.0000000000002816. [Epub ahead of print]

Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome. 2016


[4] Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome. Garnock-Jones KP1. Drugs. 2016 Jul;76(10):1031-40. doi: 10.1007/s40265-016-0601-4.

Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome. 2016


[5] Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.Ferini-Strambi L1, Marelli S1, Galbiati A1. Expert Opin Drug Metab Toxicol. 2016 Jun 16:1-9. [Epub ahead of print]

Outcomes of long-term iron supplementation in pediatric restless legs syndrome/periodic limb movement disorder (RLS/PLMD). 2016


[6] Outcomes of long-term iron supplementation in pediatric restless legs syndrome/periodic limb movement disorder (RLS/PLMD). Dye TJ1, Jain SV2,

________________________________________________________________________________________________________________

Intractable restless legs syndrome: role of prolonged-release oxycodone-naloxone 2016

[1] Intractable restless legs syndrome: role of prolonged-release oxycodone-naloxone. de Biase S, Valente M, Gigli GL. Neuropsychiatr Dis Treat. 2016 Feb 23;12:417-25. doi: 10.2147/NDT.S81186. eCollection 2016. 

Treatment Options in Intractable Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) feb 2016

[2] Treatment Options in Intractable Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED). Rinaldi F, Galbiati A, Marelli S, Ferini Strambi L, Zucconi M.

Incidence of Augmentation in Primary Restless Legs Syndrome Patients May Not Be That High: Evidence From A Systematic Review and Meta-Analysis jan 2016

[3] Incidence of Augmentation in Primary Restless Legs Syndrome Patients May Not Be That High: Evidence From A Systematic Review and Meta-Analysis. Liu GJ, Wu L, et al. Medicine (Baltimore). 2016 Jan;95(2):e2504. doi: 10.1097/MD.0000000000002504.

Frequent difficulties in the treatment of restless legs syndrome - case report and literature review. 2015

[4] Frequent difficulties in the treatment of restless legs syndrome – case report and literature review. Narowska D, Bożek M, et al. Psychiatr Pol. 2015;49(5):921-930. doi: 10.12740/PP/35395

Restless legs syndrome in migraine patients: prevalence and severity. mar 2016

[5] Restless legs syndrome in migraine patients: prevalence and severity. van Oosterhout WP, van Someren EJ, et al. Eur J Neurol. 2016 Mar 21. doi: 10.1111/ene.12993.

Restless legs syndrome in hemodialysis patients 2016 MAR APR

[6] Restless legs syndrome in hemodialysis patients. Rafie S, Jafari M1, Azizi M, et al. Saudi J Kidney Dis Transpl. 2016 Mar-Apr;27(2):326-30. doi: 10.4103/1319-2442.178553

Reduced bone resorption and increased bone mineral density in women with restless legs syndrome. 2016 Feb 26

[7] Reduced bone resorption and increased bone mineral density in women with restless legs syndrome. Cikrikcioglu MA, Sekin Y, et al. Neurology. 2016 Feb 26. pii: 10.1212/WNL.0000000000002521.

Patterns of increased intrinsic functional connectivity in patients with restless legs syndrome are associated with attentional control of sensory inputs. 2016 Feb 26

[8] Patterns of increased intrinsic functional connectivity in patients with restless legs syndrome are associated with attentional control of sensory inputs. Gorges M, Rosskopf J, et al. Neurosci Lett. 2016 Mar 23;617:264-9. doi: 10.1016/j.neulet.2016.02.043. Epub 2016 Feb 26

Alternative treatment of restless legs syndrome: an overview of the evidence for mind-body interventions, lifestyle interventions, and neutraceuticals 2015 Dec 3

[9] Alternative treatment of restless legs syndrome: an overview of the evidence for mind-body interventions, lifestyle interventions, and neutraceuticals. Bega D, Malkani R. Sleep Med. 2016 Jan;17:99-105. doi: 10.1016/j.sleep.2015.09.009. Epub 2015 Dec 3


__________________________________________________________________________________________________

Onderzoek betreffende Pregabaline, feb 2014


http://wedinfo.blogspot.com/2014/02/study-sheds-light-on-treatment-for.html

Willis-Ekbom Disease Foundation

Study sheds light on treatment for Willis-Ekbom disease (restless legs syndrome): Pregabalin (Lyrica) found as effective as FDA-approved pramipexole (Mirapex) without causing the worsening of symptoms that commonly occurs with pramipexole.

Rochester, Minn. – February 20, 2014 – A large-scale study of treatment for Willis-Ekbom disease (restless legs syndrome, or WED/RLS) published February 14 in the New England Journal of Medicine shows that the drug pregabalin (Lyrica) controls symptoms as well as pramipexole (Mirapex), but with significantly lower incidence of augmentation. Augmentation is a worsening of symptoms with long-term use, and occurs in about one third of WED/RLS patients who take the intermediate-acting dopamine drugs pramipexole and ropinirole (Requip). Both pramipexole and ropinirole are FDA approved for treating WED/RLS and commonly used as first-line therapy.

“Over the long term, the most commonly used treatments for WED/RLS make a bad disease worse,” saysRichard P. Allen, PhD, who is first author of the report. Allen is an associate professor in the Department of Neurology at Johns Hopkins University past chair of the WED Foundation’s medical advisory board.

“This study is an important contribution to our knowledge of the treatment of a widespread and very serious medical condition,” said Karla Dzienkowski, executive director of the Willis-Ekbom Disease Foundation, headquartered in Rochester, Minn.

WED/RLS is a disease that produces an overwhelming evening and nighttime urge to move the legs. It wreaks havoc on sleep, disrupts quality of life, and is associated with increased risk of cardiovascular disease. Clinically significant WED/RLS affects from 2 to 3 percent of adults and progressively worsens over time.

Wetenschappelijke onderzoeken naar RLS te vinden in pubmed

The long-term treatment of restless legs syndrome/Willis–Ekbom disease: a report from the International Restless Legs Syndrome Study Group, mei 2013

Diego Garcia-Borreguero, Ralf Kohnen, Michael H. Silber, John W. Winkelman, Christopher J. Earley, Birgit Högl, Mauro Manconi, Jacques Montplaisir, Yuichi Inoue, Richard P. Allen

Received 25 January 2013; received in revised form 29 May 2013; accepted 31 May 2013.

Abstract   Full Text   PDF   References   Supplemental Materials

Abstract Dissociation of periodic leg movements from arousals in restless legs syndrome, Annals of Neurology 2012, Volume 71

Objective:

The purpose of this study was to characterize the nature of the relation between periodic leg movements during sleep (PLMS) and cortical arousals to contribute to the debate on the clinical significance and treatment of PLMS.

Methods:

A prospective, placebo-controlled, single-blind, parallel group study was carried out including 46 drug-naive patients with idiopathic restless legs syndrome (RLS). Each patient underwent 2 consecutive full-night polysomnographic studies. The first night was the baseline night. Prior to the second night, 1 group received a single oral dose of 0.25mg pramipexole, whereas a second group received a single oral dose of 0.5mg clonazepam, and the remaining patients received placebo. Sleep stages, cyclic alternating pattern (CAP), and leg movement activity were scored following standard criteria; symptoms of RLS were also assessed.

Results:

Pramipexole suppressed PLMS without affecting electroencephalographic (EEG) instability (CAP) and arousals (corresponding to CAP A3 and, partially, A2 subtypes), whereas clonazepam did the opposite, reducing non-rapid eye movement sleep EEG instability without effects on PLMS. Both drugs were effective on sensory RLS symptoms.

Interpretation:

This study demonstrates that a selective pharmacological approach can disconnect PLMS from arousal events, suggesting an indirect relation between each other. These results might weaken the hypothesis of a direct pathological role of PLMS in sleep disruption and can be important for the discussion on the existence of a distinct entity called periodic limb movements disorder. Moreover, the study opens the doors to the possibility of a joint treatment for RLS targeting sensory and motor symptoms, as well as sleep instability.

Mauro Manconi MD1,*, Raffaele Ferri MD2, Marco Zucconi MD3, Claudio L. Bassetti MD1, Stephany Fulda PhD1, Debora Aricò PsyD, PhD2, Luigi Ferini-Strambi MD3 Article first published online: 20 JUN 2012

Nieuwe richtlijn voor behandeling restless legs syndrome

De European Federation of Neurological Societies (EFNS) heeft in samenwerking met de European Neurological Society en de European Sleep Research Society nieuwe richtlijnen gepubliceerd voor de behandeling van het restless legs syndrome (RLS) in het vakblad Annals of Neurology.

Volgende geneesmiddelen worden aanbevolen voor een kortdurende behandeling van RLS: rotigotine, ropinirol, pramipexol, gabapentine enacarbil, gabapentine en pregabaline.

Voor landurige behandeling wordt alleen rotigotine als effectief beschouwd, gabapentine enacarbil als waarschijlijk effectief, en ropinirol, pramipexol en gabapentine als mogeljk effectief. Cabergoline wordt niet aanbevolen omwille van het risico op ernstige bijwerkingen.

verschenen op : 02-01-2013 (www.gezondheid.be)

TREATMENT OF RLS AND PLMS DISORDER IN ADULTS: PRACTICE PARAMETERS

SLEEP, Vol. 35, No. 8, 2012

Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis, Annals of Neurology 2011, Volume 70

Abstract

Restless legs syndrome (RLS) is a frequent sleep disorder that is linked to disturbed iron homeostasis. Genetic studies identified MEIS1 as an RLS-predisposing gene, where the RLS risk haplotype is associated with decreased MEIS1 mRNA and protein expression. We show here that RNA interference treatment of the MEIS1 worm orthologue increases ferritin expression in Caenorhabditis elegans and that the RLS-associated haplotype leads to increased expression of ferritin and DMT1 in RLS brain tissues. Additionally, human cells cultured under iron-deficient conditions show reduced MEIS1 expression. Our data establish a link between the RLS MEIS1 gene and iron metabolism.

Hélène Catoire PhD1, Patrick A. Dion PhD1,2, Lan Xiong MD, PhD1,3, Mourabit Amari MD1, Rebecca Gaudet MSc1, Simon L. Girard MSc1, Anne Noreau MSc1, Claudia Gaspar PhD1,2, Gustavo Turecki MD, PhD4, Jacques Y. Montplaisir MD, PhD5,6, J. Alex Parker PhD1,2, Guy A. Rouleau MD, PhD1,3,7,*

Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome

The Lancet Neurology, Volume 10, Issue 8, Pages 710 – 720, August 2011 doi:10.1016/S1474-4422(11)70127-2

Algorithms for the diagnosis and treatment of restless legs syndrome in primary care

BMC Neurology 2011, 11:28 doi:10.1186/1471-2377-11-28

Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases

Sleep Disorders Volume 2011 (2011), Article ID 468952, 6 pages doi:10.1155/2011/468952

Ropinirole (Requip®) and Pramipexole (Mirapex®) for the Treatment of Primary Restless Legs Syndrome

 World of Drug Information Volume 19 Issue 1 March 2008

Long-term Treatment of Restless Legs Syndrome With Dopamine Agonists

Arch Neurol. 2004;61(9):1393-1397. doi:10.1001/archneur.61.9.1393

NTVG, Geen verschil in werkzaamheid tussen hydrokinine en placebo bij het restless legs-syndroom, 29-04-1991

 Ned Tijdschr Geneeskd. 1991;135:759-63, Onderzoek naar de werkzaamheid van hydrokinine bij het restless legs-syndroom